This is a non-core endpoint: only basic statistics are computed.
See these related core endpoints for full statistics:
Use of trihexyphenidyl
PDMED_TRIHEXYPHENIDYL
No definition available.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
519972 |
1. Apply sex-specific ruleNone |
519972 |
2. Check conditionsNone |
519972 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
1 out of 7 registries used, show all original rules. |
64 |
4. Check minimum number of events
Min. number of events
3
|
64 |
5. Include endpointsNone |
64 |
6. Filter based on genotype QC (FinnGen only) |
61 |
Control definitions (FinnGen only)
Controls for this endpoint are individuals that are not cases.
Extra metadata
- First used in FinnGen datafreeze
- DF2
Use of trihexyphenidyl
based on the number of shared cases.
Similar with more cases:
Similar with less cases:
Summary Statistics
↥-FinRegistry-
This endpoint is excluded from FinRegistry analyses (omitted endpoint).
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 61 | 32 | 29 |
| Unadjusted period prevalence (%) | 0.01 | 0.01 | 0.01 |
| Median age at first event (years) | 51.39 | 41.21 | 62.62 |
-FinnGen-
Age distribution of first events
-FinnGen-
Year distribution of first events
-FinnGen-
Cumulative Incidence Function
Not a core endpoint, no data to show.
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 64
- Matched controls
- 640
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
N04AA01
ATC
trihexyphenidyl; oral
+∞
91.9
64
*
N04AA02
ATC
biperiden; systemic
169.7
38.0
37
5
110
Kela drug reimbursment
Parkinson's disease and comparable movement disrorders
106.5
33.8
35
7
112
Kela drug reimbursment
Severe psychotic and other severe mental disorders
64.7
32.6
37
13
G20
ICD-10 Finland
Parkinson disease
49.9
19.6
23
7
N05AA02
ATC
levomepromazine; systemic
49.9
19.6
23
7
N04BA02
ATC
levodopa and decarboxylase inhibitor; oral
37.3
19.1
24
10
F20.9
ICD-10 Finland
Schizophrenia, unspecified
61.0
18.7
21
5
Z76.8
ICD-10 Finland
Persons encountering health services in other specified circumstances
28.3
18.4
25
14
N05AF05
ATC
zuclopenthixol; systemic
71.2
18.2
20
*
N05AX08
ATC
risperidone; systemic
11.0
17.9
24
33
N05AH03
ATC
olanzapine; systemic
26.5
17.3
24
14
N05BA01
ATC
diazepam; systemic, rectal
8.4
15.0
26
48
N05BA06
ATC
lorazepam; systemic, sublingual
17.5
14.9
24
21
N05AH02
ATC
clozapine; systemic
+∞
14.1
13
*
N05AB03
ATC
perphenazine; systemic, rectal
29.8
12.3
16
7
N03AE01
ATC
clonazepam; systemic
17.4
12.1
19
15
F20
ICD-10 Finland
Schizophrenia
145.0
11.9
12
*
N05AF03
ATC
chlorprothixene; systemic
43.9
11.8
14
*
N05AH04
ATC
quetiapine; oral
7.1
11.8
23
47
F20.00
ICD-10 Finland
Paranoid schizophrenia continuous
31.9
10.3
13
5
N05CD07
ATC
temazepam; oral
5.7
9.7
24
61
29510
ICD-8 Finland
Schizophrenia, Hebephrenic type
+∞
9.6
9
*
188
Kela drug reimbursment
Psychosis requiring demanding treatment
+∞
9.6
9
*
P72
ICPC
Schizophrenia
28.9
9.3
12
5
N04BD01
ATC
selegiline; oral
28.9
9.3
12
5
N04BB01
ATC
amantadine; oral
58.3
9.0
10
*
N05AX12
ATC
aripiprazole; systemic
32.6
8.8
11
*
F20.0
ICD-10 Finland
Paranoid schizophrenia
103.1
8.6
9
*
F20.1
ICD-10 Finland
Hebephrenic schizophrenia
+∞
8.5
8
*
3320A
ICD-9 Finland
Parkinson's disease, Paralysis agitans
51.5
7.9
9
*
A06AD11
ATC
lactulose; oral
4.9
7.9
23
66
2951C
ICD-9 Finland
Schizophrenic psychoses, Disorganised type[HEBEFREENISTYYPPINEN SKITSOFRENIA,KROONINEN]
+∞
7.4
7
*
U04
ICPC
Incontinence urine
13.1
7.1
12
11
SPAT1262
SPAT
Handing over of treatment supplies
4.7
7.0
20
56
N04BX02
ATC
entacapone; oral
44.9
6.9
8
*
F20.10
ICD-10 Finland
Raise schizophrenia continuously
77.2
6.6
7
*
ZY000
NOMESCO Finland
Hospital inpatient
77.2
6.6
7
*
GD1QA
NOMESCO Finland
Supine thorax X-ray examination
4.1
6.6
24
81
ZXE01
NOMESCO Finland
Procedure duration 0 to 9 minutes
30.0
6.4
8
*
G02CB01
ATC
bromocriptine; systemic
30.0
6.4
8
*
N03AG01
ATC
valproic acid; systemic, rectal
10.2
6.4
12
14
AA400
NOMESCO Finland
Electroconvulsive therapy
+∞
6.3
6
*
ZXY49
NOMESCO Finland
Other health care provider
+∞
6.3
6
*
N06AB04
ATC
citalopram; systemic
4.0
6.3
24
83
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
27
41
10.66
18.72
7.1
3.6
—
—
—
0
0
32
127
4.04
7.04
6.9
3.5
0.00
0.00
estimate
-0.00
23
40
25
95
3.68
5.67
2.2
1.9
392.87
550.51
pmol/l
2.06
15
86
11
18
7.13
4.85
7.6
4.5
26.82
24.91
mmol/l
0.45
11
18
34
176
2.99
4.44
6.9
3.6
—
—
—
0
0
8
10
8.94
4.19
6.9
2.5
28.97
27.46
mmol/l
—
8
10
10
18
6.37
4.17
2.1
1.4
—
—
—
0
0
21
98
2.70
3.15
3.0
1.5
1659.82
1221.70
nmol/l
1.11
11
77
17
71
2.90
3.12
2.3
2.0
—
—
—
0
0
36
222
2.42
2.98
6.9
3.6
0.00
0.00
estimate
-0.00
24
44
35
223
2.26
2.58
7.8
4.8
0.00
0.00
estimate
-0.00
20
42
35
225
2.23
2.50
6.8
3.6
0.00
0.00
estimate
-0.00
24
37
5
9
5.91
2.25
2.0
1.3
—
—
—
0
0
8
25
3.50
2.18
1.8
1.8
—
—
—
0
0
26
170
1.89
1.61
4.3
3.1
—
—
—
0
0
33
234
1.85
1.58
12.6
15.9
1.17
1.25
inr
0.37
26
58
24
158
1.83
1.43
2.6
2.6
57.65
56.87
u/l
0.04
17
145
33
246
1.70
1.25
16.4
11.0
4.41
3.91
e9/l
0.64
28
211
29
213
1.66
1.14
5.3
6.0
1.21
1.21
mmol/l
0.00
15
187
16
100
1.80
1.10
2.8
2.1
4.88
3.13
mg/l
0.39
11
86
5
102
0.45
1.00
2.0
2.3
—
—
—
0
0
0
30
0.00
1.00
0.0
1.7
—
—
—
0
0
9
55
1.74
0.78
1.8
1.9
—
—
—
0
0
0
20
0.00
0.61
0.0
1.1
—
—
—
0
0
27
218
1.41
0.61
2.7
2.9
—
—
—
0
0
8
53
1.58
0.61
1.9
1.8
—
—
—
0
0
0
23
0.00
0.59
0.0
1.3
—
—
—
0
0
19
145
1.44
0.58
2.7
3.6
1762.29
1308.87
ng/l
0.32
14
124
15
110
1.47
0.55
1.3
1.7
1.05
1.38
mmol/l
—
8
86
37
320
1.37
0.54
3.8
4.5
10.00
12.12
mm/h
0.43
31
288
37
418
0.73
0.54
3.6
4.2
1.12
1.31
mmol/l
1.14
23
385
12
163
0.68
0.52
4.3
5.0
1.42
2.07
ug/l
—
7
134
39
432
0.75
0.45
4.1
4.8
3.96
4.60
mmol/l
2.72
25
402
20
161
1.35
0.44
1.9
3.5
2.35
2.35
mmol/l
0.03
14
138
0
15
0.00
0.42
0.0
1.5
—
—
—
0
0
0
16
0.00
0.41
0.0
1.3
—
—
—
0
0
0
16
0.00
0.41
0.0
1.1
—
—
—
0
0
0
16
0.00
0.41
0.0
1.3
—
—
—
0
0
43
467
0.76
0.40
23.2
18.4
73.09
77.73
umol/l
0.46
43
467
39
427
0.78
0.37
4.2
4.7
1.51
1.49
mmol/l
0.12
25
395
41
441
0.80
0.29
4.2
5.2
2.08
2.67
mmol/l
2.87
28
408
39
358
1.23
0.28
5.3
7.9
73.15
79.11
u/l
0.93
33
329
40
429
0.82
0.26
5.3
4.9
6.14
6.00
mmol/l
0.22
30
397
5
37
1.38
0.24
1.2
2.1
1.66
1.57
%
—
5
32
18
207
0.82
0.23
2.2
2.6
—
—
—
0
0
39
416
0.84
0.22
6.9
5.8
41.32
40.01
mmol/mol
0.37
29
391
0
11
0.00
0.21
0.0
1.2
—
—
—
0
0
0
11
0.00
0.21
0.0
1.3
—
—
—
0
0
0
11
0.00
0.21
0.0
1.0
—
—
—
0
0
0
10
0.00
0.21
0.0
1.3
—
—
—
0
0
0
13
0.00
0.21
0.0
1.3
—
—
—
0
0
0
13
0.00
0.21
0.0
1.5
—
—
—
0
0
0
13
0.00
0.21
0.0
1.3
—
—
—
0
0
12
140
0.82
0.17
1.8
3.8
21.50
27.56
u/l
2.91
12
128
42
403
1.12
0.11
5.7
5.0
1.62
1.96
mu/l
1.52
37
369
19
174
1.13
0.11
1.5
2.0
88.68
95.01
pmol/l
0.25
11
85
16
174
0.89
0.09
1.9
2.1
69.45
76.30
nmol/l
0.32
11
148
5
60
0.82
0.08
2.4
1.3
—
—
—
0
0
7
63
1.12
0.08
5.3
5.1
3.74
2.34
mmol/l
—
7
49
38
378
1.01
0.00
26.0
17.3
15.34
15.29
%
0.02
38
370
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.5
—
43.62
—
0
6
0
5
0.00
-0.00
0.0
2.4
—
848.00
—
0
5
0
8
0.00
-0.00
0.0
2.4
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.7
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
5
0.00
-0.00
0.0
2.2
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
2.35
—
0
5
0
9
0.00
-0.00
0.0
4.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
8
0.00
-0.00
0.0
2.4
—
—
—
0
0
0
7
0.00
-0.00
0.0
2.9
—
178.86
—
0
7
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.3
—
215.17
—
0
6
0
6
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
5
0.00
-0.00
0.0
2.2
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
5
0.00
-0.00
0.0
2.6
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.1
—
11.67
—
0
7
0
5
0.00
-0.00
0.0
1.4
—
18.40
—
0
5
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
4.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.7
—
—
—
0
0
0
5
0.00
-0.00
0.0
2.6
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
5
0.00
-0.00
0.0
6.2
—
198.14
—
0
5
0
5
0.00
-0.00
0.0
2.6
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
9.00
—
0
5
0
5
0.00
-0.00
0.0
2.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
2.2
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
Mortality – FinRegistry
↥This endpoint is excluded from FinRegistry analyses (omitted endpoint).
Relationships between endpoints
↥Index endpoint: PDMED_TRIHEXYPHENIDYL – Use of trihexyphenidyl
GWS hits: -
This endpoint is excluded from FinRegistry analyses (omitted endpoint).